生物制剂对银屑病关节炎外周关节影像学进展的影响:荟萃分析
该荟萃分析纳入11项研究、5382例银屑病关节炎患者,评估生物制剂对外周关节影像学进展的疗效。结果显示,与安慰剂相比,生物制剂组影像学无进展比例更高(OR 2.40,95%CI 2.00–2.87),影像学进展评分变化更低(SMD -2.16,95%CI -2.91至-1.41)。合并MTX治疗未显示额外获益,既往抗TNF治疗不影响IL抑制剂的影像学疗效。
要点
- 生物制剂较安慰剂显著提高银屑病关节炎患者影像学无进展比例(OR 2.40)。
- TNF抑制剂和IL抑制剂均显著降低影像学进展评分(SMD分别为-2.82和-1.60)。
- 合并MTX治疗未较单药治疗显示额外影像学获益(SMD 0.01)。
核心结论
- 生物制剂可能延缓银屑病关节炎患者外周关节的影像学进展(骨侵蚀和关节间隙狭窄),优于安慰剂。
- MTX似乎没有额外影像学获益。
- 既往抗TNF治疗似乎不影响IL阻断剂的影像学疗效。
研究设计与样本
- 荟萃分析,检索MEDLINE、Web of Science及末次EULAR和ACR会议摘要至2019年12月31日。
- 纳入11项研究,涉及5382例患者、9种药物、18种治疗方案。
主要发现
- 生物制剂组影像学无进展比例高于安慰剂(合并OR 2.40,95%CI 2.00–2.87;TNFi OR 2.94,95%CI 2.38–3.63;ILi OR 2.15,95%CI 1.69–2.74;阿巴西普OR 1.54,95%CI 1.03–2.28)。
- 生物制剂组影像学进展评分变化显著低于安慰剂(合并SMD -2.16,95%CI -2.91至-1.41;TNFi SMD -2.82,95%CI -4.31至-1.33;ILi SMD -1.60,95%CI -2.49至-0.72;阿巴西普SMD -0.40,95%CI -0.59至-0.21)。
- 合并MTX与单药治疗相比影像学进展无差异(合并SMD 0.01,95%CI -0.07至0.08;生物制剂SMD 0.01,95%CI -0.09至0.11;安慰剂SMD -0.01,95%CI -0.13至0.12)。
- 乌司奴单抗和司库奇尤单抗的影像学疗效不受既往抗TNF治疗影响(SMD -0.08,95%CI -0.25至0.10)。
关键数值与推荐
- 主要终点:第24周影像学无进展患者比例。
- 次要终点:第24周总影像学评分平均变化。
- 生物制剂较安慰剂影像学无进展OR 2.40(95%CI 2.00–2.87)。
临床怎么用
- 对于银屑病关节炎患者,生物制剂可考虑用于延缓外周关节影像学进展。
- 合并MTX可能不增加影像学保护作用,但需结合临床其他获益综合决策。
- 既往抗TNF治疗失败者使用IL抑制剂仍可能获得影像学获益。
局限性
- 检索截止2019年12月31日,未纳入此后发表的研究。
- 纳入研究间存在异质性,部分亚组分析基于少量研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the efficacy of biologics in preventing radiographic progression in peripheral joints of PsA patients. METHODS: Studies were searched in MEDLINE, Web of Science, and abstracts from the last three EULAR and ACR meetings up to 31 December 2019. Primary and secondary endpoints were the proportion of patients without radiographic progression and the mean change in total radiographic score at week 24. RESULTS: Eleven studies, involving 5382 patients, 9 drugs and 18 treatments, were included. Patients receiving biologics were more likely to achieve radiographic non-progression compared with placebo [odds ratio: pooled: 2.40, 95% CI: 2.00, 2.87; TNF inhibitors (TNFi): 2.94, 95% CI: 2.38, 3.63; IL inhibitors (ILi): 2.15, 95% CI: 1.69, 2.74; abatacept: 1.54, 95% CI: 1.03, 2.28] and have significantly lower radiographic progression [standardized mean difference (SMD): pooled: -2.16, 95% CI: -2.91, -1.41; TNFi: -2.82, 95% CI: -4.31, -1.33; ILi: -1.60, 95% CI: -2.49, -0.72; abatacept: -0.40, 95% CI: -0.59, -0.21]. Concomitant MTX therapy was not superior to monotherapy (SMD: pooled: 0.01, 95% CI: -0.07, 0.08; biologics: 0.01, 95% CI: -0.09, 0.11; placebo: -0.01, 95% CI: -0.13, 0.12). The effect of ustekinumab and secukinumab on radiographic progression was not influenced by prior anti-TNF therapy (SMD: -0.08, 95% CI: -0.25, 0.10). CONCLUSION: Biologic agents may retard radiographic progression in PsA patients in terms of bone erosion and joint space narrowing compared with placebo. MTX seems to have no added effect. Prior anti-TNF therapy seems to not influence the radiographic efficacy of IL blockers.
引用
- Wu D, Li C, Zhang S, et al. Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis. Rheumatology (Oxford). 2020. PMID: 32756993. doi:10.1093/rheumatology/keaa313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。